Clinical Trial Update: Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy [Phase 2]

View source ↗

Summary

Phase II study of high-dose rituximab in high-risk chronic lymphocytic leukemia patients who had suboptimal response to induction immunochemotherapy has been te…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia

Drugs mentioned

• Rituximab (rituximab)

Snippet

Sponsor: Cliniques universitaires Saint-Luc- Université Catholique de Louvain | Conditions: Chronic Lymphocytic Leukemia | Phase 2 | Status: TERMINATED